» Articles » PMID: 11762345

Relationship Between Neuroendocrine Features and Prognostic Parameters in Human Prostate Adenocarcinoma

Overview
Journal Ann Oncol
Publisher Elsevier
Specialty Oncology
Date 2002 Jan 5
PMID 11762345
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The biological behaviour of prostate cancer is highly variable and prediction by the commonly employed prognostic parameters is not sufficient. The concept of neuroendocrine (NE) differentiation in prostate adenocarcinoma has recently received increasing attention due to possible implications for prognosis and therapy.

Materials And Methods: Core needle biopsies from 142 newly diagnosed patients were immunohistochemically examined for the coexistence of NE differentiation using an antibody against chromogranin A (CgA). Circulating CgA was available in 106 of these patients.

Results: NE differentiation was found in 64 (45.1%) tumors. Among them 29 (20.4%) had CgA positive cells scattered or focally distributed in less than 5% per mm3 of tumor tissues, 26 (18.3%) between 5% and 10% and 9 (6.4%) more than 10%, respectively. There was a significant correlation between the extent of NE features and either Gleason score (P < 0.01) or stage of disease. Circulating CgA but not PSA correlated with immunohistochemical CgA (P < 0.03) particularly in metastatic cases.

Conclusions: These data support the concept that NE differentiation in human prostate cancer has a negative prognostic significance. Circulating CgA levels reflect immunohistochemical findings.

Citing Articles

Prognostic value of circulating Chromogranin A in prostate cancer: a systematic review and meta-analysis.

Tang X, Liu Z, Song L, Zhu H, Su S, Wang D Front Oncol. 2025; 15:1521558.

PMID: 39975592 PMC: 11835686. DOI: 10.3389/fonc.2025.1521558.


Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation.

Bergamini M, Dalla Volta A, Caramella I, Bercich L, Fisogni S, Bertoli M Front Oncol. 2022; 12:937713.

PMID: 35936689 PMC: 9354022. DOI: 10.3389/fonc.2022.937713.


Mixed adenoneuroendocrine carcinoma of the urethra.

Raison N, McGovern U, Hines J, Volanis D BMJ Case Rep. 2019; 12(3).

PMID: 30902843 PMC: 6453422. DOI: 10.1136/bcr-2018-227948.


Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer.

Giridhar K, Sanhueza C, Hillman D, Alkhateeb H, Carlson R, Tan W Prostate Cancer Prostatic Dis. 2018; 21(3):431-437.

PMID: 29858590 PMC: 6126956. DOI: 10.1038/s41391-018-0046-9.


Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms.

La Rosa S, Sessa F, Uccella S Endocr Pathol. 2016; 27(4):284-311.

PMID: 27169712 DOI: 10.1007/s12022-016-9432-9.